11/10/2023 0 Comments Kite pharma buyout![]() She also served as Kite Pharma’s Executive Vice President and Chief Financial Officer from 2014 to 2016. ![]() Butitta served as Chief Operating Officer of Kite Pharma, where she played an instrumental role in the acquisition of Kite Pharma by Gilead Sciences for approximately $11.9 billion in cash. She has served as a director for UroGen since October 2017. Butitta is a seasoned financial and operational executive with more than 25 years of leadership experience in both the biotechnology and high-technology industries. degree in marketing from Saint Joseph's University and a B.S. Barrett also currently serves on the boards of directors of Sage Therapeutics and Allogene Therapeutics. She started her career at Kraft Foods Group, Inc. Barrett held positions at Cephalon, Inc., where she was Vice President and General Manager of the Oncology Business Unit, and at Johnson & Johnson. in various leadership capacities, most recently as the Global President of Oncology and, before that, as President of Global Innovative Pharma for Europe, President of the Specialty Care Business Unit for North America, and Regional President of United States Oncology.īefore Pfizer, Ms. Barrett was CEO of Novartis Oncology and a member of the Novartis Executive Committee since February 2018. ![]() Barrett has served as director and our President and Chief Executive Officer since January 2019. Barrett is a highly regarded industry leader with extensive experience leading business organizations and Fortune 500 pharmaceutical companies. Belldegrun is certified by the American Board of Urology and is a fellow of the American Association of Genitourinary Surgeons. He has authored several books on oncology and more than 500 scientific and medical papers related to urological cancers, immunotherapy, gene therapy, and cancer vaccines. at the Hebrew University Hadassah Medical School in Jerusalem, Israel, his post-graduate studies in immunology at the Weizmann Institute of Science, Israel, and his residency in urologic surgery at Harvard Medical School. Rosenberg at the National Cancer Institute/NIH. Belldegrun served as a research fellow in surgical oncology and immunotherapy under Dr. Belldegrun is a Professor of Urology, holds the Roy and Carol Doumani Chair in Urologic Oncology, and is Director of the UCLA Institute of Urologic Oncology at the David Geffen School of Medicine at UCLA. He serves as Executive Chairman of Allogene Chairman of Two River Group and Kronos Bio Co-Founder and Senior Managing Director of Vida Ventures, a life science venture group.ĭr. Belldegrun most recently co-founded Allogene Therapeutics, a clinical stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (CAR T) therapies for cancer. Abiraterone, developed by Cougar, is a mainstay of therapy for patients with metastatic prostate cancer.ĭr. Belldegrun has had a distinguished tenure in the life sciences and has been closely involved with the founding and advancement of several successful biopharmaceutical companies, including Cougar Biotechnology and Agensys. Belldegrun founded Kite Pharma, a biopharmaceutical company engaged in the development of innovative cancer immunotherapies, where he served as Chairman, President, and Chief Executive Officer until the acquisition of Kite by Gilead Sciences in October 2017.ĭr. He has built a distinguished career as a visionary surgeon, scientist, and life sciences entrepreneur.ĭr. Belldegrun is the Chairman of UroGen Pharma and has served as our Chair since December 2012.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |